Generex Biotechnology Participates in Gateway to China Business Round Table Conference


WORCESTER, Mass., July 7, 2010 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (Nasdaq:GNBT) today announced its participation in the Gateway to China Business Round Table Conference held in Orlando, Florida June 28 & 29.

The conference, hosted by China Direct Industries, Inc., brought together Chinese government officials, international business leaders, and key international organizations to identify opportunities for inbound and outbound investment, partnership, joint venture, and international trading in China, North America, and South America. The conference included a delegation from the China International Council for Promotion of Multi-National Corporations (CICPMC), a private organization supervised by the Ministry of Commerce in China. This organization is instrumental in helping companies raise capital, navigate through government bureaucracy, and facilitating dialogue with companies seeking to trade and invest in China.  In addition, a number of key Chinese business leaders, investment bankers, fund managers, and government officials as well as investors from China, U.S., Canada, Mexico, Chile, Columbia, and Brazil were in attendance.

"We are actively seeking to establish strategic relationships that will foster the commercialization of Generex Oral-lyn™, our proprietary buccal insulin spray product, as well as our line of over-the-counter products in China," said Anna Gluskin, the Company's President & Chief Executive Officer. "This conference was an ideal opportunity to introduce Generex and its products to an influential segment of the Chinese business community."

About Generex Biotechnology Corporation

Generex is engaged in the research, development and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. The Company's flagship product, buccal insulin (Generex Oral-lyn™), which has been approved in India, Lebanon, Algeria, and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

The Generex Biotechnology Corp. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3831

Safe Harbor Statement

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.


            

Contact Data